Avaxia Biologics raised a round of funding on February 14, 2012.
Avaxia is an early-stage biotechnology company focused on developing recombinant, gut-targeted antibody therapeutics for gastrointestinal diseases. These unique antibody therapeutics, called Avaximabs…
